Print
O and P
See Ova and Parasites, Stool

Print
Obstetric Panel		Test Code: PN1
Includes:	•ABO/Rh and Antibody Screen (PREN code-ordered separately) •CBC with Automated Differential (CBCD) •Hepatitis B Surface Antigen (HbsAg) •Rubella IgG Antibody, Immune Status (RUBG) •Rapid Plasma Reagin (RPR) •Reflexed when appropriate • Hepatitis B Surface Antigen (HbsAg) • Neutralization Confirmation on initial positive screens • Reactive RPR screens are titered and reported quantitatively •Treponemal confirmation by TP-PA methodology will be performed on all reactive RPR screens •Antibody Identification •Phenotype Antigen Test •Direct Antiglobulin Test •Antibody Elution •Antibody Titer NOTE This test should be performed on all pregnant women as early in pregnancy as possible. •For all clinically significant antibodies having reactivity greater or equal to 1+, an initial antibody titer will be performed.Subsequent titers should berequested by the physician. •Rh (D) positive women should have a repeat Prenatal Testing performed when there is a history of clinically significant red cell antibodies, previousblood transfusions, or trauma to the abdomen. •Rh (D) negative women should have a repeatPrenatal Testing performed at 28-30 weeksgestation prior to Rh (D) Immune Globulin (RhIG)administration and when other indications exist (seeRh (D) Immune Globulin for additionalinformation) •Request an Obstetric Profile, Repeat Blood BankOnly if required.
CPT:	80055,Reflexed when appropriate 87341, 86593, 86781, 86870, 86905, 86906,86880, 86860,86886
Alternate Name:	Prenatal Package 1 (No Urinalysis)
Methodology:	See individual test listings.
Testing Schedule:	Routine, daily
Report Available:	1-3 days
Special Instructions and/or Comments:
Submit specimen with a completed Blood Bank Requisition (LAB-04) Form.
Reference Range:
See individual test listings.
Clinical Utility:
See individual test listings.

Print
Obstetric Profile PREN with Urinalysis		Test Code: PN2
Includes:	•ABO/Rh and Antibody Screen (PREN code-ordered separately) •CBC with Differential (CBCD) •Hepatitis B surface Antigen (HbsAg) •Rapid Plasma Reagin (RPR) •Rubella IgG Antibody, Immune Status (RUBG) •Urinalysis (URIN) •Reflexed when appropriate ...........•Hepatitis B Surface Antigen (HbsAg) ...........•Neutralization Confirmation on initial positive screens ...........•Reactive RPR screens are titered and reported quantitatively ...........•Treponemal confirmation by TP-PA methodology will be performed on all reactive RPR screens •Antibody Identification •Phenotype Antigen Test •Direct Antiglobulin Test •Antibody Elution •Antibody Titer
CPT:	80055, 81003, 81001,Reflexed when appropriate 87341, 86593, 86781, 86870,86905, 86906, 86880, 86860,86886
Alternate Name:	Prenatal Package 2 (Includes Urinalysis)
Methodology:	See individual test listings.
Testing Schedule:	Routine, daily
Report Available:	1-3 days
Specimen Requirements:
Container:	2 Gold top (serum separator) tubes, 1 lavender top(EDTA) tube, 1 pink top (EDTA) tube AND 1plastic urine container
Special Instructions and/or Comments:
•An initial Prenatal Testing should be performedon all pregnant women as early in pregnancy aspossible. •For all clinically significant antibodies havingreactivity greater or equal to 1+, an initial antibodytiter will be performed.Subsequent titers should berequested by the physician. •Rh (D) positive women should have a repeat Prenatal Testing performed when there is a history of clinically significant red cell antibodies, previous blood transfusions, or trauma to the abdomen. •Rh (D) negative women should have a repeat Prenatal Testing performed at 28-30 weeksgestation prior to Rh (D) Immune Globulin (RhIG)administration and when other indications exist (seeRh (D) Immune Globulin for additionalinformation). •Request RPRE if required (Repeat Prenatal Testing). •Antepartum must be administered to Rh (D)negative females at 28 weeks gestation to provide protection against immunization to the D antigenduring pregnancy, provided there is no evidence of an active allo anti-D. •A standard dose of Rh (D) Immune Globulin should also be administered to all Rh (D) negative women within 72 hours following invasive obstetric procedures (such as amniocentesis, CVS, PUBS) abdominal trauma, external version, and vaginal bleeding during pregnancy. •Other obstetrical indications for RhIG includes spontaneous or therapeutic abortion, ectopic pregnancy, chronic villus sampling, cordocentesis,antepartum hemorrhage, and fetal death. •Submit specimen with a completed Blood Bank Requisition (LAB-04) Form.
Reference Range:
See individual test listings.
Clinical Utility:
See individual test listings.

Print
Obstetric Profile PREN with Urinalysis		Test Code: PN3
Includes:	•ABO/Rh and Antibody Screen (PREN code-ordered separately) •CBC with Differential (CBCD) •Hepatitis B surface Antigen (HbsAg) •Rapid Plasma Reagin (RPR) •Rubella IgG Antibody, Immune Status (RUBG) •Urinalysis (URIN) •Glucose (GLUC) •Creatinine (CREAT) •Reflexed when appropriate ..............•Hepatitis B Surface Antigen (HbsAg) Neutralization Confirmation on initial positive screens .............•Reactive RPR screens are titered and reported quantitatively .............•Treponemal confirmation by TP-PA methodology will be performed on all reactive RPR screens •Antibody Identification •Phenotype Antigen Test •Direct Antiglobulin Test •Antibody Elution •Antibody Titer
CPT:	80055, 81003, 81001,Reflexed when appropriate 87341, 86593, 86781, 86870,86905, 86906, 86880, 86860,86886
Alternate Name:	Prenatal Package (Includes Urinalysis)
Methodology:	See individual test listings.
Testing Schedule:	Routine, daily
Report Available:	1-3 days
Specimen Requirements:
Container:	2 Gold top (serum separator) tubes, 1 lavender top(EDTA) tube, 1 pink top (EDTA) tube AND 1plastic urine container
Special Instructions and/or Comments:
•An initial Prenatal Testing should be performed on all pregnant women as early in pregnancy as possible. •For all clinically significant antibodies having reactivity greater or equal to 1+, an initial antibody titer will be performed.Subsequent titers should be requested by the physician. •Rh (D) positive women should have a repeat Prenatal Testing performed when there is a history of clinically significant red cell antibodies, previous blood transfusions, or trauma to the abdomen. •Rh (D) negative women should have a repeat Prenatal Testing performed at 28-30 weeks gestation prior to Rh (D) Immune Globulin (RhIG)administration and when other indications exist (seeRh (D) Immune Globulin for additional information). •Request RPRE if required (Repeat Prenatal Testing). •Antepartum must be administered to Rh (D)negative females at 28 weeks gestation to provide protection against immunization to the D antigenduring pregnancy, provided there is no evidence of an active allo anti-D. •A standard dose of Rh (D) Immune Globulin should also be administered to all Rh (D) negative women within 72 hours following invasive obstetric procedures (such as amniocentesis, CVS, PUBS) abdominal trauma, external version, and vaginal bleeding during pregnancy. •Other obstetrical indications for RhIG includes spontaneous or therapeutic abortion, ectopic pregnancy, chronic villus sampling, cordocentesis,antepartum hemorrhage, and fetal death. •Submit specimen with a completed Blood Bank Requisition (LAB-04) Form.
Reference Range:
See individual test listings.
Clinical Utility:
See individual test listings.

Print
Obstetric Profile, Repeat Blood Bank Only		Test Code: RPRE
Includes:	NOTE An initial Prenatal Testing test should be performed on all pregnant women as early in pregnancy as possible. •ABO •Rh (D) •Antibody Screen •Reflexed when appropriate •Antibody Identification •Phenotype Antigen Test •Direct Antiglobulin Test •Antibody Elution •Antibody Titer
CPT:	86850, 86900, 86901, Reflexed when appropriate 86870, 86905, 86906, 86880, 86860, 86886
Related Information:	Antibody Titer; Type and Screen
Alternate Name:	Prenatal Screen; Prenatal Testing, Repeat Blood Bank Only; Rh (D) Immune Globulin, Testing Antepartum
Methodology:	See individual test listings.
Testing Schedule:	Routine, daily
Report Available:	1-3 days
Specimen Requirements:
Minimum Volume:	4 mL plasma
Container:	Pink top (EDTA) tube
Special Instructions and/or Comments:
•For all clinically significant antibodies having reactivity greater or equal to 1+, an initial antibodytiter will be performed.Subsequent titers should be requested by the physician. •Rh (D) positive women should have a repeat Prenatal Testing performed when there is a history of clinically significant red cell antibodies, previous blood transfusions, or trauma to the abdomen. •Rh (D) negative women should have a repeat Prenatal Testing performed at 28-30 weeks gestation prior to Rh (D) Immune Globulin (RhIG) administration and when other indications exist. •Antepartum must be administered to Rh (D) negative females at 28 weeks gestation to provideprotection against immunization to the D antigenduring pregnancy, provided there is no evidence ofan active allo anti-D. •A standard dose of Rh (D) Immune Globulin should also be administered to all Rh (D) negative women within 72 hours following invasive obstetric procedures (such as amniocentesis, CVS, PUBS)abdominal trauma, external version, and vaginalbleeding during pregnancy. •Other obstetrical indications for RhIG includespontaneous or therapeutic abortion, ectopic pregnancy, chronic villus sampling, cordocentesis,antepartum hemorrhage, and fetal death. •Submit specimen with a completed Blood Bank Requisition (LAB-04) Form.
Reference Range:
See individual test listings.

Print
Occult Blood,1 Sample Stool		Test Code: OCLT1
CPT:	82272 , 82270
Alternate Name:	Fecal Occult Blood, FOB test,Sure-Vue, Colo- Rect®; Colo-Screen®; Hema-Chek®; Hemocult®,Stool; Quick-Cult®; Stool Analysis
Methodology:	Guaiac Paper Test
Testing Schedule:	Monday-Friday, 0700-1530
Report Available:	1-3 days
Specimen Requirements:
Minimum Volume:	1 or 3 cards (3 recommended)
Container:	Collection card
Collection:	•Follow instructions for use that come with the collection kit. Obtain specimen and place sealed card into the pouch and return to the physician’s office. •Patient should not receive Vitamin C (ascorbic acid) for 3 days prior to guaiac testing. NOTE: •Antacids may cause false-positives. •A high bulk, red meat free diet with restriction of peroxidase-rich vegetables (turnips, horseradish,artichokes, mushrooms, radishes, broccoli, beansprouts, cauliflower, apples, oranges, bananas,cantaloupes, grapes), is recommended for 72 hours prior to and during guaiac testing, to decrease the incidence of false-positives. •Therapeutic iron causes false-positives in >50%of healthy subjects in guaiac testing. •Alcohol and aspirin (especially together), and other gastric irritants (steroids, rauwolfia derivatives, all nonsteroidal anti-inflammatory drugs, colchicine) should be avoided. •Halogens and cimetidine can cause reactions with guaiac tests.
Special Instructions and/or Comments:
•Immediately return the specimen to your physician’s office. •Store empty cards at room temperature.
Reference Range:
Negative.This system will detect 0.2 gm hgb/100gm of stool
Clinical Utility:
Examine stool for the presence of blood which may be associatedwith gastrointestinal disorders such as diverticulitis, polyps, and Chron’s disease that may lead to colorectal cancer.

Print
Occult Blood,3 Samples Stool		Test Code: OCLT3
CPT:	82272 , 82270
Alternate Name:	Fecal Occult Blood, FOB test,Sure-Vue, Colo-Rect®; Colo-Screen®; Hema-Chek®; Hemocult®,Stool; Quick-Cult®; Stool Analysis
Methodology:	Guaiac Paper Test
Testing Schedule:	Monday-Friday, 0700-1530
Report Available:	1-3 days
Specimen Requirements:
Minimum Volume:	1 or 3 cards (3 recommended)
Container:	collection card
Collection:	•Follow instructions for use that come with the collection kit. Obtain specimen and place sealed card into the pouch and return to the physician’s office. •Patient should not receive Vitamin C (ascorbic acid) for 3 days prior to guaiac testing. NOTE •Antacids may cause false-positives. •A high bulk, red meat free diet with restriction of peroxidase-rich vegetables (turnips, horseradish,artichokes, mushrooms, radishes, broccoli, beansprouts, cauliflower, apples, oranges, bananas,cantaloupes, grapes), is recommended for 72 hours prior to and during guaiac testing, to decrease the incidence of false-positives. •Therapeutic iron causes false-positives in >50%of healthy subjects in guaiac testing. •Alcohol and aspirin (especially together), and other gastric irritants (steroids, rauwolfia derivatives, all nonsteroidal anti-inflammatorydrugs, colchicine) should be avoided. •Halogens and cimetidine can cause reactions with guaiac tests.
Special Instructions and/or Comments:
•Immediately return the specimen to your physician’s office. •Store empty cards at room temperature.
Reference Range:
Negative.This system will detect 0.2 gm hgb/100gm of stool
Clinical Utility:
Examine stool for the presence of blood which may be associated with gastrointestinal disorders such as diverticulitis, polyps, and Chron’s disease that may lead to colorectal cancer.

Print
Occult Blood , stool, Immunoassay		Test Code: IFOBT
CPT:	82274
Alternate Name:	Hemoccult® ICT; Immunochemical Fecal Occult Blood Test
Methodology:	Immunoassay for qualitative detection of human hemoglobin
Testing Schedule:	Monday – Friday
Report Available:	1-3 days
Specimen Requirements:
Minimum Volume:	One sample; 3 samples are preferred Container Collection cards provided in Patient Screening Kit
Collection:	Follow instructions on Patient Screening Kit package
Special Instructions and/or Comments:
•No drug, vitamin, or diet restrictions •Do not take test for 3 days before, during or after menstrual period •Do not take test if you have bleeding hemorrhoids, blood in urine, open cuts on hands, or have strained during bowel movement. •Do not collect specimen from under water •Check expiration date on collection card and do not use if date has passed •After specimen has been collected and placed on collection cards, place all 3 cards in Hemoccult mailing pouch. •Affix 1 first class postage stamp and mail pouch within 10 days of collection.
Reference Range:
Negative.
Clinical Utility:
Detection of human hemoglobin in stool as an aid in the diagnosis of gastrointestinal disorders, which may lead to colorectal cancer if not treated

Print
17-OH Pregnenolone
See 17-Hydroxypregnenolone

Print
18-OH-Corticosterone
See 18-Hydroxycorticosterone

Print
Oligoclonal Banding, CSF and Serum		Test Code: OLIGB
CPT:	83916
Methodology:	Isoelectric focusing
Testing Schedule:	Routine, 3 times per week
Report Available:	5-7 days
Specimen Requirements:
Minimum Volume:	1 mL serum AND 1 mL cerebrospinal fluid
Container:	Gold top (serum separator) tube AND Sterile conical tube
Special Instructions and/or Comments:
Testing cannot be performed unless both cerebrospinal fluid AND serum are submitted.
Reference Range:
NO bands
Clinical Utility:
Diagnose diseases of the central nervous system including meningitis, tumor, syphilis, and multiple sclerosis. Generally the presence of 2 or more bands in CSF with comparable intensity in comparison to serum are considered clinically significant.

Print
Opiates, Qualitative, Urine 2000 ng/ml cutoff concentration.		Test Code: OPIA
Includes:	Screening for opiates in urine by immunoassay to include codeine, morphine, and heroin (as morphine), with a detection limit of 2000 ng/ml
CPT:	80101
Alternate Name:	Codeine; Heroin; Morphine
Methodology:	Immunoassay (IA)
Testing Schedule:	Routine, daily
Report Available:	1 day
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Special Instructions and/or Comments:
If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-53)Form.
Reference Range:
Negative NOTE: Confirmation by GC/MS (gas chromatography/mass spectrometry) available upon request. Contact Customer Care 610-402-8170 for instructions.

Print
Opiates, Qualitative, Urine 300 ng/ml cutoff concentration		Test Code: OPI3
Includes:	Screening for opiates in urine by immunoassay to include codeine, morphine, heroin (as morphine), hydromorphone, and hydrocodone with a detection limit of 300 ng/ml
CPT:	80101
Alternate Name:	Codeine; Heroin; Morphine
Methodology:	Immunoassay (IA)
Testing Schedule:	Routine, daily
Report Available:	1 day
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Special Instructions and/or Comments:
If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-53)Form.
Reference Range:
Negative NOTE: Confirmation by GC/MS (gas chromatography/mass spectrometry) available upon request. Contact Customer Care 610-402-8170 for instructions.

Print
Opiates, Free, Blood		Test Code: BFOPI
Includes:	Identification and quantitation of free (unconjugated) codeine, morphine
CPT:	83925, Codeine; Heroin; Morphine
Methodology:	Gas Chromatography / Mass Spectrometry (GC/MS)
Testing Schedule:	Routine, once per week
Report Available:	1-2 weeks
Specimen Requirements:
Minimum Volume:	2 mL whole blood
Container:	Gray top (sodium fluoride) or lavender top (EDTA) tube
Special Instructions and/or Comments:
If for medical/legal or forensic purposes, submit with Chain-of-Custody
Reference Range:
None Detected

Print
Opiates, Total, Blood		Test Code: BTO
Includes:	Identification and quantitation of total (conjugated and unconjugated) codeine, morphine, oxycodone, oxymorphone, hydrocodone and hydromorphone
CPT:	83925
Alternate Name:	Codeine; Heroin; Morphine
Methodology:	Liquid Chromatography-Tandem Mass Spectrometry
Testing Schedule:	Routine
Report Available:	5-7 days
Specimen Requirements:
Minimum Volume:	7 mL whole blood
Container:	Gray top (sodium fluoride) tube
Special Instructions and/or Comments:
If for medical/legal or forensic purposes, submit with Chain-of-Custody
Reference Range:
Blood levels are dependent on drug dosage. •Morphine: Dependent upon drug dosage •Codeine: Therapeutic: 30-340 ng/ml •Hydrocodone: Therapeutic: 30-250 ng/ml •Hydromorphone: Therapeutic: 8-50 ng/ml •Oxycodone: Therapeutic: 10-100 ng/ml •Oxymorphone: Therapeutic Range NOT established

Print
Opiates, Quantitative Low Level, Urine		Test Code: LOUO
Includes:	GC/MS analysis for opiates with low reporting limits. Includes quantitation for codeine, morphine,oxycodone, oxymorphone, hydrocodone and hydromorphone.
CPT:	83925
Methodology:	Gas Chromatography / Mass Spectrometry (GC/MS)
Testing Schedule:	Routine, 2 times per week
Report Available:	5-7 days
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Reference Range:
No reference data available.
Clinical Utility:
Useful for determining drug use/abuse or for compliance monitoring.

Print
Opiates, Urine, GCMS		Test Code: GCUO
Includes:	Identification and quantitation of opiates by GCMS for: codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone.
CPT:	83925
Methodology:	Gas Chromatography/Mass Spectroscopy (GC/MS)
Testing Schedule:	2 times/week
Report Available:	3-5 days
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Special Instructions and/or Comments:
•If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32)Form.
Reference Range:
None present
Clinical Utility:
Useful for the detection and positive identification ofspecific opiates in urine.

Print
Organic Acids, Urine		Test Code: URORG
CPT:	83919
Alternate Name:	Organic Acids Screen, Random Urine
Methodology:	Gas Chromatography/Mass Spectrometry (GC/GS)
Testing Schedule:	Routine, daily
Report Available:	7-10 days
Specimen Requirements:
Minimum Volume:	10 mL random urine (minimum 3 mL)
Container:	Plastic urine container
Special Instructions and/or Comments:
• Freeze specimen in plastic container. • DO NOT use glass. • Once frozen, transport specimen submerged in dry ice.
Reference Range:
An interpretative report will be provided
Clinical Utility:
Useful for diagnosis of inborn errors of metabolism.

Print
Osmol, Serum
See Osmolality, SerumOsmol, Urine
See Osmolality, Urine

Print
Osmolality, Serum		Test Code: OSM
CPT:	83930
Alternate Name:	Osmol, Serum; Serum Osmolality
Methodology:	Freezing-point Depression
Testing Schedule:	Routine, STAT testing available
Report Available:	1 day
Special Instructions and/or Comments:
Transport to laboratory within 1 hour. If delay in transport, centrifuge, transfer to plastic aliquot tube and refrigerate.
Reference Range:
279-295 mOsm/kg
Critical Values:
•<250 mOsm/kg •>325 mOsm/kg
Clinical Utility:
Used to evaluate electrolyte, water and acid/base balance; hyperosmolar and hydration status; and to aid in the screen for the presence of certain low molecular weight. toxins.

Print
Osmolality, Stool		Test Code: STOS
CPT:	83935
Alternate Name:	Stool Osmolality
Methodology:	Freeing-point Depression
Testing Schedule:	Routine, STAT testing available
Report Available:	1 day
Specimen Requirements:
Minimum Volume:	5 mL liquid stool
Container:	Plastic urine container
Special Instructions and/or Comments:
Refrigerate
Reference Range:
220-280 mOsm/kg
Clinical Utility:
Used to evaluate chronic diarrhea.

Print
Osmolality, Urine		Test Code: UROS
CPT:	83935
Alternate Name:	Osmol, Urine; Urine Osmolality
Methodology:	Freezing Point Depression
Testing Schedule:	Routine, STAT testing available
Report Available:	1 day
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Special Instructions and/or Comments:
Refrigerate
Reference Range:
300-900 mOsm/kg
Clinical Utility:
Used to evaluate concentrating ability of the kidneys,urinary output and electrolyte and water balance.

Print
Osmotic Fragility, Erythrocyte		Test Code: RFGB
Includes:	•Unincubated fragility test using NaCl solution 0.50 g/dL •24-Hour Incubated fragility test at NaCl concentrations of 0.60, 0.65 and 0.75 g/dL
CPT:	85557
Alternate Name:	• Erythrocyte Osmotic Fragility • RBC Fragility • RBC Osmotic Fragility • Red Cell Fragility
Methodology:	Manual
Testing Schedule:	Routine, Monday-Friday only
Report Available:	4-5 days
Specimen Requirements:
Minimum Volume:	5.0 mL in lavender top (EDTA) tube
Container:	1 lavender top (EDTA) tube
Collection:	NOTE: A “normal” control” sample (from someone unrelated to the patient) must be drawn and submitted under the same conditions as the patient specimen. Please label this sample as “Normal Control” and send it along with the patient’s sample. Also, write the age and sex of the person used as the normal control on the tube. Contact our Referral Testing Department at 610-402-5864 for special instructions prior to obtaining specimen.
Special Instructions and/or Comments:
• Collect Monday-Friday ONLY, NO Holidays. • Specimens must arrive in the laboratory no later than 1600. • Store as whole blood in original tube at room temperature. • DO NOT centrifuge, aliquot or freeze.
Reference Range:
0.50 g/dL NaCl (unincubated) •Males...........................0.0-47.8% hemolysis •Females ......................0.0-31.1% hemolysis ...........................................0.60 g/dL NaCl (incubated) •Males..........................18.7-67.4% hemolysis •Females......................10.9-65.5% hemolysis ..........................................0.65 g/dL NaCl (incubated) •Males..........................4.4-36.6% hemolysis •Females.......................0.2-39.3% hemolysis ..........................................0.75 g/dL NaCl (incubated) •Males..........................0.8-9.1% hemolysis •Females......................0.0-10.9% hemolysis
Clinical Utility:
Useful for, suspected hereditary spherocytic hemolytic anemia.

Print
Osteocalcin		Test Code: OCALC
CPT:	83937
Methodology:	Electrochemiluminescence Immunoassay
Testing Schedule:	Routine, daily
Report Available:	3-5 dauly
Specimen Requirements:
Minimum Volume:	1 mL serum
Container:	Gold top (serum separator) tube
Collection:	Draw in the morning after a 12 hour fast
Special Instructions and/or Comments:
Centrifuge, transfer serum to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice.
Reference Range:
• <18 years........................Not established • > 18 years....................9-42 ng/mL
Clinical Utility:
Monitoring and assessing effectiveness of antiresorptive therapy in patients treated for osteopenia, osteroporosis, Paget’s disease, or other disorders in which osteocalcin levels are elevated

Print
Otitis Media Allergen Profile
See Allergen Profile, Otitis Media

Print
Outside Slide Review, Surgical Pathology
See Histopathology, Surgical Pathology Consultation, Outside Slides

Print
Ova and Parasite, Gross Worm Identification
See Parasite Identification

Print
Ova and Parasites, Stool		Test Code: OP
Includes:	•Wet Prep •Concentration procedure •Trichrome smear
CPT:	87177, 87209
Alternate Name:	Isospora; O and P; Parasites, Stool; Stool for Ova and Parasite
Methodology:	Sedimentation centrifugation/concentration technique, trichrome stain, microscopic evaluation
Testing Schedule:	Routine, Monday-Friday only
Report Available:	1-3 days
Specimen Requirements:
Minimum Volume:	Fresh semi-formed OR liquid stool submitted in Para-Pak® container with 10% formalin and Zn-PVA fixative, filled to red line.DO NOT use if fluid is yellow.
Collection:	•The recommended screening procedure is three random stool specimens; one collected everyother day. Specimen is placed in polyvinyl alcohol (PVA) for permanent stains and 10% formalin for concentration preparations and direct examination. •Collect specimen in dry container. •Use spoons attached to cap of parasitology tubes to transfer. •Both vials should be filled from same bowel movement. •Specimens obtained with a warm saline enema or Fleet® Phospho®-Soda are acceptable. •Specimens obtained with mineral oil, bismuth,iron, or magnesium compounds are NOT acceptable. •Wait 1 week or more after barium procedures or barium laxatives before collecting stools for examination.
Reference Range:
No ova or parasites observed.Test does not look for Cryptosporidium, Cyclospora and Microsporidium.
Clinical Utility:
Parasitic diseases around the world have one of the highest morbidity and mortality rates.Proper diagnosis of intestinal parasitic infections relys on proper collection, transport and identification of parasites in stool specimens.Because of the erratic way parasites are shed in the stool, it is important to submit multiple specimens.

Print
Ovarian Antibody
See Ovarian Autoantibody

Print
Ovarian Cancer Monitoring		Test Code: HE4OV
CPT:	86305
Methodology:	Enzyme Immunoassay
Testing Schedule:	Routine, 2 times per week
Report Available:	7-10 days
Specimen Requirements:
Minimum Volume:	1 mL (minimum 0.1)
Container:	Red top tube (serum separator is also accaptable)
Special Instructions and/or Comments:
Centrifuge specimen, refrigerate
Reference Range:
< 150 pM
Clinical Utility:
Elevated HE4 levels are associated with ovarian cancer but are not disease specific. A change in HE4 level of > or = 25% is considered significant. An increase of this magnitude suggests recurrence of disease progression while a decrease of this magnitude suggests therapeutic response.

Print
Ovarian Tumor Marker
See CA-125

Print
Oxalate, Quantitative, 24-Hour Urine		Test Code: 24OXA
Includes:	•Volume Measurement •Collection Period •Oxalate, Urine
CPT:	81050, 83945
Alternate Name:	Oxalic Acid, Urine
Methodology:	Enzymatic, using oxalate oxidase
Testing Schedule:	Routine, daily
Report Available:	5-7 days
Specimen Requirements:
Minimum Volume:	25 mL aliquot of a well-mixed 24-Hour urine collection
Container:	24-Hour plastic urine container, no preservative
Collection:	•Instruct the patient to void at the beginning of the collection period and discard the specimen. •Collect all urine including the final specimen voided at the end of the collection period. •Refrigerate during collection. •Container must be labeled with the patient’s name.
Special Instructions and/or Comments:
•Instruct the patient not to void directly into the container. •Transport to the laboratory promptly.
Reference Range:
9.7-40.5 mg/specimen
Clinical Utility:
Useful For monitoring therapy for kidney stones. Identifying increased urinary oxalate as a risk factor for stone formation. Diagnosis of primary or secondary hyperoxaluria.

Print
Oxalic Acid, Urine
See Oxalate, Quantitative, 24-Hour Urine

Print
Oxcarbazepine Metabolite		Test Code: TRIL
CPT:	80299
Alternate Name:	• Trileptal • MHC (Oxcarbazepine Metabolite)
Methodology:	High Tubulence Liquid Chromatography Mass Spectroscopy (HTLC- MS/MS)
Testing Schedule:	Routine, daily
Report Available:	3-5 days
Specimen Requirements:
Minimum Volume:	1 mL serum
Container:	Red top tube, no serum separator
Collection:	Collect immediately before next scheduled dose.
Special Instructions and/or Comments:
• Spin down within 2 hours of draw • Refrigerate
Reference Range:
3 to 35 mcg/mL The therapeutic range (3 to 35 mcg/mL) is based on concentrations of the metabolite (MHC) not the parent drug, this assay measures the metabolite only.
Clinical Utility:
Useful for monitoring oxcarbazepine therapy and assessing compliance.

Print
Oxcarbazepine
See Trileptal

Print
Oxycodone, Qualitative, Urine		Test Code: OXYC
Includes:	Screening for oxycodone and oxymorphone, cutoff concentration 100 ng/ml.
CPT:	80101
Alternate Name:	Percocet, Oxycontin
Methodology:	Immunoassay (IA)
Testing Schedule:	Routine, daily
Report Available:	1 day
Specimen Requirements:
Minimum Volume:	5 mL random urine
Container:	Plastic urine container
Special Instructions and/or Comments:
• This is a qualitative screen and result is reported as positive or negative. • Confirmation and/or quantitation of a positive screening result by GC/MS is available upon request by calling Toxicology Lab at (610) 402-5850. • Chain of custody optional.
Reference Range:
Negative unless taking medications containing oxycodone or oxymorphone.
Clinical Utility:
Detect the ingestion and/or use of oxycodone or oxymorphone for monitoring compliance or drug abuse.